Patient suffering from opioid induced hyperalgesi (OIH).
Conditions
Interventions
Trade Name: Naloxone
Product Name: Naloxon
Pharmaceutical Form: Injection*
Product Name: Propofol-Lipuro
Pharmaceutical Form: Injection*
Trade Name: Catapresan
Product Name: Catapresan
Pharmaceutica
Sponsors
Karolinska University Hospital Huddinge
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - men and women between 18-70 years old - with a opioid induced hyperalgesi - have tried conventional detoxification without success - no allergy to IMP - have to quit smoking approxiamatly 3 months before enetring trial - women have to use anticonception during study and after three months of study period ending Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - seroius disease or other clinical symtoms indication underlying disorder according to American Society of Anasetsia classification system.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate patients the feasability of a rapid opioid detoxification (ROD);Secondary Objective: To evaluate patients experience in Quality of life and pain after rapid opioid detoxification (ROD);Primary end point(s): EQ-5D scale, VAS scale, Sickness Impact profile, HospitalAnxiety and Depression Scale. | — |
Countries
Sweden
Outcome results
None listed